DENVER — Researchers developed a patient-reported outcome instrument to assess the effects of anti-VEGF agents or panretinal photocoagulation for diabetic retinopathy, according to a study presented here at the ARVO meeting. Diana Do, MD, of Byers Eye Institute, Stanford University, said patients can use the Diabetic Retinopathy Scale to provide feedback on visual symptoms, emotional impact and health-related quality of life changes.